{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T11:43:09Z","timestamp":1769082189057,"version":"3.49.0"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100008865","name":"Xiamen University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.cca.2020.12.019","type":"journal-article","created":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T11:22:51Z","timestamp":1608636171000},"page":"66-73","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Lipid-lowering therapy: Guidelines to precision medicine"],"prefix":"10.1016","volume":"514","author":[{"given":"Xin","family":"Su","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2020.12.019_b0005","article-title":"New insight into sortilin in controlling lipid metabolism and the risk of atherogenesis","author":"Su","year":"2019","journal-title":"Biol. Rev. Camb. Philos. Soc."},{"issue":"7","key":"10.1016\/j.cca.2020.12.019_b0010","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrcardio.2017.31","article-title":"Hypertriglyceridaemia and risk of coronary artery disease","volume":"14","author":"Reiner","year":"2017","journal-title":"Nat. Rev. Cardiol."},{"issue":"1","key":"10.1016\/j.cca.2020.12.019_b0015","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/HCR.0b013e318192754e","article-title":"A review of lipid management in primary and secondary prevention","volume":"29","author":"Dembowski","year":"2009","journal-title":"J. Cardiopulm. Rehabil. Prev."},{"issue":"1","key":"10.1016\/j.cca.2020.12.019_b0020","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12933-018-0785-x","article-title":"The negative effect of ANGPTL8 on HDL-mediated cholesterol efflux capacity","volume":"17","author":"Luo","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"issue":"1","key":"10.1016\/j.cca.2020.12.019_b0025","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/MOL.0000000000000382","article-title":"Inflammation, remodeling, and other factors affecting HDL cholesterol efflux","volume":"28","author":"Ronsein","year":"2017","journal-title":"Curr. Opin. Lipidol."},{"issue":"19","key":"10.1016\/j.cca.2020.12.019_b0030","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.2015.15629","article-title":"Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US preventive services task force","volume":"316","author":"Chou","year":"2016","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.cca.2020.12.019_b0035","doi-asserted-by":"crossref","first-page":"E367","DOI":"10.1503\/cmaj.111017","article-title":"The effect of rosuvastatin on incident pneumonia: results from the JUPITER trial","volume":"184","author":"Novack","year":"2012","journal-title":"CMAJ"},{"issue":"10","key":"10.1016\/j.cca.2020.12.019_b0040","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1161\/hc1002.105136","article-title":"Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?","volume":"105","author":"Simes","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.cca.2020.12.019_b0045","doi-asserted-by":"crossref","DOI":"10.1002\/clc.23347","article-title":"Trends in prevalence of guideline-based use of lipid-lowering therapy in a large health system","author":"Sidebottom","year":"2020","journal-title":"Clin. Cardiol."},{"issue":"9976","key":"10.1016\/j.cca.2020.12.019_b0050","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials","volume":"385","author":"Fulcher","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.cca.2020.12.019_b0055","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ijcard.2012.03.127","article-title":"How to control residual cardiovascular risk despite statin treatment: focusing on HDL-cholesterol","volume":"166","author":"Lim","year":"2013","journal-title":"Int. J. Cardiol."},{"issue":"4","key":"10.1016\/j.cca.2020.12.019_b0060","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jacc.2007.05.057","article-title":"Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials","volume":"51","author":"Iakoubova","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9493","key":"10.1016\/j.cca.2020.12.019_b0065","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"C. Cholesterol treatment trialists, efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.cca.2020.12.019_b0070","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1161\/CIRCULATIONAHA.117.032318","article-title":"Triglyceride-rich lipoprotein cholesterol and risk of cardiovascular events among patients receiving statin therapy in the TNT trial","volume":"138","author":"Vallejo-Vaz","year":"2018","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.cca.2020.12.019_b0075","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jacc.2007.10.038","article-title":"Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial","volume":"51","author":"Miller","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.cca.2020.12.019_b0080","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/dom.13537","article-title":"Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin-controlled LDL cholesterol","volume":"21","author":"Nichols","year":"2019","journal-title":"Diab. Obes. Metab."},{"issue":"39","key":"10.1016\/j.cca.2020.12.019_b0085","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"E.S.C.S.D. group, 2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.cca.2020.12.019_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1248\/bpb.b15-00716","article-title":"Metabolism and modification of apolipoprotein B-containing lipoproteins involved in dyslipidemia and atherosclerosis","volume":"39","author":"Morita","year":"2016","journal-title":"Biol. Pharm. Bull."},{"issue":"3","key":"10.1016\/j.cca.2020.12.019_b0095","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCOUTCOMES.110.959247","article-title":"A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk","volume":"4","author":"Sniderman","year":"2011","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"issue":"9359","key":"10.1016\/j.cca.2020.12.019_b0100","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)12663-3","article-title":"Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment","volume":"361","author":"Sniderman","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.cca.2020.12.019_b0105","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.cca.2020.01.015","article-title":"The exchangeable apolipoproteins in lipid metabolism and obesity","volume":"503","author":"Su","year":"2020","journal-title":"Clin. Chim. Acta"},{"issue":"4","key":"10.1016\/j.cca.2020.12.019_b0110","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jacl.2011.05.004","article-title":"Reliability of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B measurement","volume":"5","author":"Contois","year":"2011","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.cca.2020.12.019_b0115","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.atherosclerosis.2018.05.010","article-title":"Non-HDL-C levels and residual cardiovascular risk: do population-specific precision approaches offer any advantages?","volume":"274","author":"Enkhmaa","year":"2018","journal-title":"Atherosclerosis"},{"issue":"22","key":"10.1016\/j.cca.2020.12.019_b0120","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1161\/CIRCULATIONAHA.104.532499","article-title":"Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men","volume":"112","author":"Pischon","year":"2005","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.cca.2020.12.019_b0125","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1177\/2047487315569411","article-title":"Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C","volume":"22","author":"Pencina","year":"2015","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.cca.2020.12.019_b0130","unstructured":"Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel members, an international atherosclerosis society position paper: global recommendations for the management of dyslipidemia\u2013full report, J. Clin. Lipidol. 8(1) (2014) 29\u201360."},{"key":"10.1016\/j.cca.2020.12.019_b0135","doi-asserted-by":"crossref","first-page":"g4356","DOI":"10.1136\/bmj.g4356","article-title":"Development, Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance","volume":"349","author":"Rabar","year":"2014","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.cca.2020.12.019_b0140","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1194\/jlr.R082735","article-title":"Cholesteryl ester transfer protein and its inhibitors","volume":"59","author":"Shrestha","year":"2018","journal-title":"J. Lipid Res."},{"issue":"5","key":"10.1016\/j.cca.2020.12.019_b0145","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1161\/CIRCULATIONAHA.111.018259","article-title":"Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the investigation of lipid level management to understand its impact in atherosclerotic events (ILLUMINATE) trial","volume":"124","author":"Barter","year":"2011","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.cca.2020.12.019_b0150","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ahj.2015.09.007","article-title":"Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: rationale and design of the ACCELERATE trial","volume":"170","author":"Nicholls","year":"2015","journal-title":"Am. Heart J."},{"key":"10.1016\/j.cca.2020.12.019_b0155","doi-asserted-by":"crossref","first-page":"g4379","DOI":"10.1136\/bmj.g4379","article-title":"Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients","volume":"349","author":"Keene","year":"2014","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.cca.2020.12.019_b0160","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa1001689","article-title":"Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis","volume":"364","author":"Khera","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.cca.2020.12.019_b0165","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/MED.0000000000000530","article-title":"Triglycerides and residual risk","volume":"27","author":"Vallejo-Vaz","year":"2020","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"issue":"1","key":"10.1016\/j.cca.2020.12.019_b0170","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/2047487316673142","article-title":"An evaluation of the performance of SCORE Sweden 2015 in estimating cardiovascular risk: the Northern Sweden MONICA Study 1999\u20132014","volume":"24","author":"Karjalainen","year":"2017","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"29","key":"10.1016\/j.cca.2020.12.019_b0175","first-page":"2259","article-title":"Limitations of the SCORE-guided European guidelines on cardiovascular disease prevention","volume":"38","author":"Mortensen","year":"2017","journal-title":"Eur. Heart J."},{"issue":"5","key":"10.1016\/j.cca.2020.12.019_b0180","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1177\/1741826711412039","article-title":"S. investigators, Relationships between body mass index, cardiovascular mortality, and risk factors: a report from the SCORE investigators","volume":"18","author":"Dudina","year":"2011","journal-title":"Eur. J. Cardiovasc. Prev. Rehabil."},{"issue":"1","key":"10.1016\/j.cca.2020.12.019_b0185","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12872-018-0823-3","article-title":"Effect of blood pressure and total cholesterol measurement on risk prediction using the Systematic COronary Risk Evaluation (SCORE)","volume":"18","author":"Ulbricht","year":"2018","journal-title":"BMC Cardiovasc. Disord."},{"issue":"1","key":"10.1016\/j.cca.2020.12.019_b0190","doi-asserted-by":"crossref","first-page":"20","DOI":"10.7326\/M17-3011","article-title":"Clinical implications of revised pooled cohort equations for estimating atherosclerotic cardiovascular disease risk","volume":"169","author":"Yadlowsky","year":"2018","journal-title":"Ann. Intern. Med."},{"issue":"2 Suppl","key":"10.1016\/j.cca.2020.12.019_b0195","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/2047487312448986","article-title":"Critical appraisal of trials for validation of 'risk-guided' cardiovascular disease prevention therapy","volume":"19","author":"Castro","year":"2012","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"4","key":"10.1016\/j.cca.2020.12.019_b0200","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.amjcard.2012.10.037","article-title":"Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial)","volume":"111","author":"Ballantyne","year":"2013","journal-title":"Am. J. Cardiol."},{"issue":"21","key":"10.1016\/j.cca.2020.12.019_b0205","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1016\/j.jacc.2013.07.045","article-title":"Non-high-density lipoprotein cholesterol, guideline targets, and population percentiles for secondary prevention in 1.3 million adults: the VLDL-2 study (very large database of lipids)","volume":"62","author":"Elshazly","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"10.1016\/j.cca.2020.12.019_b0210","doi-asserted-by":"crossref","first-page":"477","DOI":"10.5551\/jat.33100","article-title":"Relationship between non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol in the general population","volume":"23","author":"Kuwabara","year":"2016","journal-title":"J. Atheroscler. Thromb."},{"key":"10.1016\/j.cca.2020.12.019_b0215","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cca.2019.06.022","article-title":"Goals of non-high density lipoprotein cholesterol need to be adjusted in Chinese acute coronary syndrome patients: findings from the CCC-ACS project","volume":"496","author":"Su","year":"2019","journal-title":"Clin. Chim. Acta"},{"issue":"10","key":"10.1016\/j.cca.2020.12.019_b0220","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1001\/archneurol.2010.240","article-title":"Lipid profile components and risk of ischemic stroke: a role for the pleiotropic effects of statins","volume":"67","author":"Connick","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.cca.2020.12.019_b0225","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ijcard.2016.10.084","article-title":"Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: the PCSK9-REACT study","volume":"227","author":"Navarese","year":"2017","journal-title":"Int. J. Cardiol."},{"issue":"3","key":"10.1016\/j.cca.2020.12.019_b0230","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jacc.2006.04.070","article-title":"Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy","volume":"48","author":"Cannon","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.cca.2020.12.019_b0235","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jacc.2016.11.037","article-title":"Safety of very low low-density lipoprotein cholesterol levels with alirocumab: pooled data from randomized trials","volume":"69","author":"Robinson","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.cca.2020.12.019_b0240","doi-asserted-by":"crossref","first-page":"e014129","DOI":"10.1161\/JAHA.119.014129","article-title":"Effect of evolocumab on non-high-density lipoprotein cholesterol, Apolipoprotein B, and Lipoprotein(a): a pooled analysis of phase 2 and phase 3 studies","volume":"9","author":"Toth","year":"2020","journal-title":"J. Am. Heart Assoc."},{"issue":"12","key":"10.1016\/j.cca.2020.12.019_b0245","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa1105803","article-title":"Effect of a monoclonal antibody to PCSK9 on LDL cholesterol","volume":"366","author":"Stein","year":"2012","journal-title":"N Engl. J. Med."},{"issue":"18","key":"10.1016\/j.cca.2020.12.019_b0250","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Investigators, evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl. J. Med."},{"issue":"16","key":"10.1016\/j.cca.2020.12.019_b0255","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","article-title":"Cardiovascular efficacy and safety of bococizumab in high-risk patients","volume":"376","author":"Ridker","year":"2017","journal-title":"N Engl. J. Med."},{"issue":"14","key":"10.1016\/j.cca.2020.12.019_b0260","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1093\/eurheartj\/ehx549","article-title":"2017 Update of ESC\/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin\/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia","volume":"39","author":"Landmesser","year":"2018","journal-title":"Eur. Heart J."},{"issue":"15","key":"10.1016\/j.cca.2020.12.019_b0265","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at high cardiovascular Risk with elevated LDL cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N Engl. J. Med."},{"issue":"3","key":"10.1016\/j.cca.2020.12.019_b0270","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/13543784.2018.1442435","article-title":"Inclisiran for the treatment of dyslipidemia","volume":"27","author":"Nishikido","year":"2018","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"5","key":"10.1016\/j.cca.2020.12.019_b0275","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jjcc.2017.10.017","article-title":"New hope for hyperlipidemia management: inclisiran","volume":"71","author":"Bandyopadhyay","year":"2018","journal-title":"J. Cardiol."},{"issue":"6","key":"10.1016\/j.cca.2020.12.019_b0280","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2217\/fca-2018-0067","article-title":"Inclisiran for the treatment of cardiovascular disease: the ORION clinical development program","volume":"14","author":"Stoekenbroek","year":"2018","journal-title":"Future Cardiol."},{"issue":"9860","key":"10.1016\/j.cca.2020.12.019_b0285","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"F.H.L.S.i. Phase 3 Ho, Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.cca.2020.12.019_b0290","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40256-017-0214-7","article-title":"Efficacy and safety of lomitapide in hypercholesterolemia","volume":"17","author":"Liu","year":"2017","journal-title":"Am. J. Cardiovasc. Drugs"},{"issue":"5","key":"10.1016\/j.cca.2020.12.019_b0295","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1080\/14740338.2019.1602606","article-title":"Review of the long-term safety of lomitapide: a microsomal triglycerides transfer protein inhibitor for treating homozygous familial hypercholesterolemia","volume":"18","author":"Khoury","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"issue":"9719","key":"10.1016\/j.cca.2020.12.019_b0300","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.cca.2020.12.019_b0305","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/14656566.2018.1550071","article-title":"Mipomersen and its use in familial hypercholesterolemia","volume":"20","author":"Parham","year":"2019","journal-title":"Expert Opin. Pharmac."},{"key":"10.1016\/j.cca.2020.12.019_b0310","doi-asserted-by":"crossref","first-page":"107459","DOI":"10.1016\/j.pharmthera.2019.107459","article-title":"Lipid-modifying therapy in chronic kidney disease: pathophysiological and clinical considerations","volume":"207","author":"Heine","year":"2020","journal-title":"Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.cca.2020.12.019_b0315","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40265-017-0858-2","article-title":"Lipid management in chronic kidney disease: systematic review of PCSK9 targeting","volume":"78","author":"Zheng-Lin","year":"2018","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.cca.2020.12.019_b0320","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.kint.2016.02.026","article-title":"Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences","volume":"90","author":"Vaziri","year":"2016","journal-title":"Kidney Int."},{"issue":"3","key":"10.1016\/j.cca.2020.12.019_b0325","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2174\/1871529X14666140401112654","article-title":"Cardiovascular disease burden and risk factors before and after kidney transplant","volume":"14","author":"Keddis","year":"2014","journal-title":"Cardiovasc. Hematol. Disord. Drug Targets"},{"issue":"6","key":"10.1016\/j.cca.2020.12.019_b0330","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1016\/j.transproceed.2018.03.115","article-title":"Cardiovascular disease in kidney transplantation and its association with blood concentrations of cyclosporine and cyclosporine metabolites","volume":"50","author":"Hryniewiecka","year":"2018","journal-title":"Transplant. Proc."},{"issue":"12","key":"10.1016\/j.cca.2020.12.019_b0335","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.3760\/cma.j.issn.0366-6999.20140518","article-title":"Effects of tacrolimus and cyclosporine treatment on metabolic syndrome and cardiovascular risk factors after renal transplantation: a meta-analysis","volume":"127","author":"Xue","year":"2014","journal-title":"Chin. Med. J. (Engl.)"},{"issue":"5","key":"10.1016\/j.cca.2020.12.019_b0340","article-title":"HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis","author":"Palmer","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.cca.2020.12.019_b0345","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrneph.2017.155","article-title":"Dyslipidaemia in nephrotic syndrome: mechanisms and treatment","volume":"14","author":"Agrawal","year":"2018","journal-title":"Nat. Rev. Nephrol."},{"issue":"3","key":"10.1016\/j.cca.2020.12.019_b0350","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"I. Dialysis Study, Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.cca.2020.12.019_b0355","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.kint.2017.12.011","article-title":"Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease","volume":"93","author":"Toth","year":"2018","journal-title":"Kidney Int."},{"issue":"8","key":"10.1016\/j.cca.2020.12.019_b0360","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.autrev.2018.02.007","article-title":"Impact of obesity on autoimmune arthritis and its cardiovascular complications","volume":"17","author":"Van Raemdonck","year":"2018","journal-title":"Autoimmun Rev."},{"key":"10.1016\/j.cca.2020.12.019_b0365","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jpba.2019.06.005","article-title":"Lipidomics in autoimmune diseases with main focus on systemic lupus erythematosus","volume":"174","author":"Ferreira","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"2","key":"10.1016\/j.cca.2020.12.019_b0370","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s12026-016-8892-9","article-title":"Dyslipidemia in systemic lupus erythematosus","volume":"65","author":"Szabo","year":"2017","journal-title":"Immunol. Res."},{"issue":"9","key":"10.1016\/j.cca.2020.12.019_b0375","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1177\/0961203307081113","article-title":"Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort","volume":"16","author":"Urowitz","year":"2007","journal-title":"Lupus"},{"issue":"10","key":"10.1016\/j.cca.2020.12.019_b0380","first-page":"2137","article-title":"Natural history of hypercholesterolemia in systemic lupus erythematosus","volume":"26","author":"Bruce","year":"1999","journal-title":"J. Rheumatol."},{"issue":"1","key":"10.1016\/j.cca.2020.12.019_b0385","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1191\/0961203306lu2269ed","article-title":"Epidemiology of systemic lupus erythematosus at the change of the millennium: lessons from the Euro-Lupus and the LUMINA projects","volume":"15","author":"Cervera","year":"2006","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.cca.2020.12.019_b0390","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.numecd.2017.09.001","article-title":"Disease trends over time and CD4(+)CCR5(+) T-cells expansion predict carotid atherosclerosis development in patients with systemic lupus erythematosus","volume":"28","author":"Baragetti","year":"2018","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"issue":"2","key":"10.1016\/j.cca.2020.12.019_b0395","doi-asserted-by":"crossref","first-page":"358","DOI":"10.12669\/pjms.332.12410","article-title":"Frequency of dyslipidemia in patients with lupus nephritis","volume":"33","author":"Sajjad","year":"2017","journal-title":"Pak. J. Med. Sci."},{"issue":"3","key":"10.1016\/j.cca.2020.12.019_b0400","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.ijcard.2014.08.006","article-title":"Increased risk of acute myocardial infarction and mortality in patients with systemic lupus erythematosus: two nationwide retrospective cohort studies","volume":"176","author":"Lin","year":"2014","journal-title":"Int. J. Cardiol."},{"issue":"5","key":"10.1016\/j.cca.2020.12.019_b0405","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1080\/08820139.2019.1567534","article-title":"A Meta-analysis of cardiovascular events in systemic lupus erythematosus","volume":"48","author":"Gu","year":"2019","journal-title":"Immunol. Invest."},{"key":"10.1016\/j.cca.2020.12.019_b0410","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.vph.2016.01.006","article-title":"Effects of synthetic and biological disease modifying antirheumatic drugs on lipid and lipoprotein parameters in patients with rheumatoid arthritis","volume":"81","author":"Naerr","year":"2016","journal-title":"Vascul. Pharmacol."},{"issue":"11","key":"10.1016\/j.cca.2020.12.019_b0415","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1080\/14740338.2017.1372421","article-title":"Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry)","volume":"16","author":"Perez-De-Lis","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.cca.2020.12.019_b0420","doi-asserted-by":"crossref","first-page":"b2376","DOI":"10.1136\/bmj.b2376","article-title":"The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials","volume":"338","author":"Brugts","year":"2009","journal-title":"BMJ"},{"issue":"22","key":"10.1016\/j.cca.2020.12.019_b0425","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1016\/j.jacc.2013.07.069","article-title":"Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis","volume":"62","author":"Savarese","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"issue":"12","key":"10.1016\/j.cca.2020.12.019_b0430","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1007\/s00228-013-1570-0","article-title":"Efficacy and safety evaluation of intensive statin therapy in older patients with coronary heart disease: a systematic review and meta-analysis","volume":"69","author":"Yan","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"8","key":"10.1016\/j.cca.2020.12.019_b0435","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.clinthera.2013.06.006","article-title":"Effects of aggressive statin therapy on patients with coronary saphenous vein bypass grafts: a systematic review and meta-analysis of randomized, controlled trials","volume":"35","author":"Kang","year":"2013","journal-title":"Clin. Ther."},{"issue":"5","key":"10.1016\/j.cca.2020.12.019_b0440","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.amjopharm.2012.08.002","article-title":"The effect of HMG-CoA reductase inhibitors on cognition in patients with Alzheimer's dementia: a prospective withdrawal and rechallenge pilot study","volume":"10","author":"Padala","year":"2012","journal-title":"Am. J. Geriatr. Pharmac."},{"issue":"10","key":"10.1016\/j.cca.2020.12.019_b0445","doi-asserted-by":"crossref","first-page":"688","DOI":"10.7326\/0003-4819-159-10-201311190-00007","article-title":"Statins and cognitive function: a systematic review","volume":"159","author":"Richardson","year":"2013","journal-title":"Ann. Intern. Med."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898120305878?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898120305878?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T14:57:17Z","timestamp":1757861837000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898120305878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":89,"alternative-id":["S0009898120305878"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2020.12.019","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipid-lowering therapy: Guidelines to precision medicine","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2020.12.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}